SG10201806787VA - Modulators of complement factor b - Google Patents

Modulators of complement factor b

Info

Publication number
SG10201806787VA
SG10201806787VA SG10201806787VA SG10201806787VA SG10201806787VA SG 10201806787V A SG10201806787V A SG 10201806787VA SG 10201806787V A SG10201806787V A SG 10201806787VA SG 10201806787V A SG10201806787V A SG 10201806787VA SG 10201806787V A SG10201806787V A SG 10201806787VA
Authority
SG
Singapore
Prior art keywords
modulators
complement factor
complement
factor
cfb
Prior art date
Application number
SG10201806787VA
Inventor
Tamar Grossman
Michael Mccaleb
Andrew Watt
Susan Freier
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of SG10201806787VA publication Critical patent/SG10201806787VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21047Alternative-complement-pathway C3/C5 convertase (3.4.21.47), i.e. properdin factor B
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/334Modified C
    • C12N2310/33415-Methylcytosine

Abstract

MODULATORS OF COMPLEMENT FACTOR B The embodiments methods, and tions treating, or ameliorating disease with of complement pathway administering a Complement Factor B (CFB) specific inhibitor to a subject. No Figure
SG10201806787VA 2013-09-13 2014-09-12 Modulators of complement factor b SG10201806787VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361877624P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
SG10201806787VA true SG10201806787VA (en) 2018-09-27

Family

ID=52666522

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201806787VA SG10201806787VA (en) 2013-09-13 2014-09-12 Modulators of complement factor b
SG11201601445XA SG11201601445XA (en) 2013-09-13 2014-09-12 Modulators of complement factor b

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201601445XA SG11201601445XA (en) 2013-09-13 2014-09-12 Modulators of complement factor b

Country Status (33)

Country Link
US (4) US20160222389A1 (en)
EP (2) EP3603677A1 (en)
JP (3) JP6666250B2 (en)
KR (1) KR102381790B1 (en)
CN (2) CN105744959B (en)
AU (2) AU2014318580B2 (en)
BR (1) BR112016004671B1 (en)
CA (1) CA2921842A1 (en)
CL (2) CL2016000606A1 (en)
CR (1) CR20160170A (en)
DK (1) DK3043827T3 (en)
DO (1) DOP2016000063A (en)
EA (1) EA035433B1 (en)
ES (1) ES2745758T3 (en)
HK (1) HK1225638A1 (en)
HR (1) HRP20191600T1 (en)
HU (1) HUE045109T2 (en)
IL (1) IL244095A0 (en)
LT (1) LT3043827T (en)
MA (1) MA38959A1 (en)
MX (2) MX371518B (en)
MY (1) MY181251A (en)
PE (2) PE20160500A1 (en)
PH (1) PH12016500443A1 (en)
PL (1) PL3043827T3 (en)
PT (1) PT3043827T (en)
RS (1) RS59252B1 (en)
RU (1) RU2662967C2 (en)
SG (2) SG10201806787VA (en)
SI (1) SI3043827T1 (en)
UA (1) UA119046C2 (en)
WO (1) WO2015038939A2 (en)
ZA (1) ZA201601236B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3916095A1 (en) 2006-10-18 2021-12-01 Ionis Pharmaceuticals, Inc. Antisense compounds
EP3467109A1 (en) 2011-02-08 2019-04-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
BR112015027321A8 (en) 2013-05-01 2018-01-02 Isis Pharmaceuticals Inc COMPOUNDS AND COMPOSITIONS FOR MODULING APOLIPOPROTEIN(A) EXPRESSION AND THEIR USES
HUE045109T2 (en) * 2013-09-13 2019-12-30 Ionis Pharmaceuticals Inc Modulators of complement factor b
JP6710638B2 (en) * 2013-12-12 2020-06-17 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Complement component iRNA composition and method of using the same
ES2745825T3 (en) 2014-05-01 2020-03-03 Ionis Pharmaceuticals Inc Compositions and methods for modulating expression of complement factor B
WO2017135397A1 (en) * 2016-02-05 2017-08-10 協和発酵キリン株式会社 Antisense oligonucleotide for suppressing expression of complement b factor
EP3448389B1 (en) 2016-06-27 2021-09-29 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
WO2018117253A1 (en) * 2016-12-23 2018-06-28 協和発酵キリン株式会社 Nucleic acid inhibiting expression of complement factor b
TW201909925A (en) * 2017-08-02 2019-03-16 日商協和醱酵麒麟有限公司 Nucleic acid complex
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
JP2023523790A (en) * 2020-04-30 2023-06-07 アルナイラム ファーマシューティカルズ, インコーポレイテッド COMPLEMENT FACTOR B (CFB) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
BR112023001195A2 (en) 2020-08-07 2023-02-28 Shanghai Meiyue Biotech Dev Co Ltd COMPOUND OR RACEMATE, STEREOISOMER, TAUTOMER, ISOTOPICALLY LABELED COMPOUND, SOLVATE, POLYMORPH, PHARMACEUTICALLY ACCEPTABLE SALT OR PRODRUG COMPOUND THEREOF, COMPOUND, METHOD OF PREPARATION FOR COMPOUND OR RACEMATE, STEREOISOMER, TAUTOMER, ISOTOPICALLY LABELED COMPOUND, POLYFOLD, SALTED, SALTED ACCEPTABLE PHARMACEUTICALLY OR PRODRUG COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR TREAT A DISEASE ASSOCIATED WITH ALTERNATIVE COMPLEMENT PATHWAY ACTIVATION, AND, USE OF THE COMPOUND
CN114057692B (en) 2020-08-07 2023-07-21 上海美悦生物科技发展有限公司 Heterocyclic compound, preparation method and application thereof
IL310180A (en) * 2021-07-17 2024-03-01 Sirnaomics Inc Products and compositions
CA3230589A1 (en) 2021-09-02 2023-03-09 Sibylle DAMES Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
TW202333749A (en) * 2021-10-29 2023-09-01 美商艾拉倫製藥股份有限公司 Complement factor b (cfb) irna compositions and methods of use thereof
WO2023129496A2 (en) * 2021-12-27 2023-07-06 Apellis Pharmaceuticals, Inc. Rnas for complement inhibition

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (en) 1984-07-19 1989-02-17 Centre Nat Rech Scient NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
DK0497875T3 (en) 1989-10-24 2000-07-03 Gilead Sciences Inc 2'-modified oligonucleotides
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DK0455905T3 (en) 1990-05-11 1998-12-07 Microprobe Corp Dipsticks for nucleic acid hybridization assays and method for covalent immobilization of oligonucleotides
ES2103918T3 (en) 1991-10-17 1997-10-01 Ciba Geigy Ag BICYCLE NUCLEOSIDES, OLIGONUCLEOTIDES, PROCEDURE FOR THEIR OBTAINING AND INTERMEDIATE PRODUCTS.
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
FR2687679B1 (en) 1992-02-05 1994-10-28 Centre Nat Rech Scient OLIGOTHIONUCLEOTIDES.
EP0577558A2 (en) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
RU95114435A (en) 1992-12-14 1997-05-20 Ханивелл Инк. (Us) System incorporating brushless dc motor
DE69404289T2 (en) 1993-03-30 1998-02-19 Sanofi Sa ACYCLIC NUCLEOSIDE ANALOGS AND THEIR OLIGONUCLEOTIDE SEQUENCES
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
WO2005121371A2 (en) 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (en) 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
JP4236812B2 (en) 1997-09-12 2009-03-11 エクシコン エ/エス Oligonucleotide analogues
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
WO2000021559A2 (en) * 1998-10-09 2000-04-20 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
WO2000066604A2 (en) 1999-05-04 2000-11-09 Exiqon A/S L-ribo-lna analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
AU2698301A (en) 1999-12-30 2001-07-16 K.U. Leuven Research And Development Cyclohexene nucleic acids
JP2005504020A (en) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド Nuclease resistant chimeric oligonucleotide
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
EP2325303B1 (en) * 2002-09-13 2013-11-06 Life Technologies Corporation Thermostable reverse transcriptases and uses thereof
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004044139A2 (en) 2002-11-05 2004-05-27 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
PT2284266E (en) 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Sirna targeting tp53
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
WO2004103288A2 (en) 2003-05-13 2004-12-02 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of preventing recurrent miscarriages
JP4731324B2 (en) 2003-08-28 2011-07-20 武 今西 N-O bond cross-linked novel artificial nucleic acid
EP1677822B1 (en) 2003-09-18 2014-04-23 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
JP5137053B2 (en) * 2004-02-10 2013-02-06 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト Anti-factor B antibody or antigen-binding fragment thereof, composition containing the same, antigen-binding polypeptide, and therapeutic agent
CN101052717A (en) * 2004-05-11 2007-10-10 α基因株式会社 Polynucleotide causing RNA interfere and method of regulating gene expression with the use of the same
JP2008513507A (en) * 2004-09-17 2008-05-01 アイシス ファーマシューティカルズ インコーポレイティッド Enhanced antisense oligonucleotides
WO2006047842A2 (en) 2004-11-08 2006-05-11 K.U. Leuven Research And Development Modified nucleosides for rna interference
GB0521716D0 (en) * 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
KR101304071B1 (en) 2006-01-27 2013-09-06 아이시스 파마수티컬즈 인코포레이티드 6-modified bicyclic nucleic acid analogs
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
CA2663601C (en) * 2006-09-22 2014-11-25 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by rna interference
CN101589143A (en) * 2006-11-27 2009-11-25 Isis药物公司 Methods for treating hypercholesterolemia
EP2125852B1 (en) 2007-02-15 2016-04-06 Ionis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
AU2008221287A1 (en) * 2007-03-01 2008-09-04 Wellstat Immunotherapeutics, Llc Treatment of diseases characterized by inflammation
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
CA2730203C (en) * 2008-07-10 2016-12-13 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement antagonists and uses thereof
DK2361256T3 (en) 2008-09-24 2013-07-01 Isis Pharmaceuticals Inc Cyclohexenyl-nucleic acid analogues
EP3173419A1 (en) 2010-04-28 2017-05-31 Ionis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
ES2756326T3 (en) * 2010-07-19 2020-04-27 Ionis Pharmaceuticals Inc Modulation of myotonic dystrophy-protein kinase (DMPK) expression
ES2634450T3 (en) * 2011-04-13 2017-09-27 Ionis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
HUE045109T2 (en) 2013-09-13 2019-12-30 Ionis Pharmaceuticals Inc Modulators of complement factor b
ES2745825T3 (en) * 2014-05-01 2020-03-03 Ionis Pharmaceuticals Inc Compositions and methods for modulating expression of complement factor B

Also Published As

Publication number Publication date
EP3043827A4 (en) 2017-05-24
WO2015038939A3 (en) 2015-07-02
US20200149047A1 (en) 2020-05-14
UA119046C2 (en) 2019-04-25
MA38959A1 (en) 2017-08-31
DK3043827T3 (en) 2019-08-26
HK1225638A1 (en) 2017-09-15
CL2018002334A1 (en) 2018-12-14
JP6666250B2 (en) 2020-03-13
US20220243209A1 (en) 2022-08-04
US20190048351A1 (en) 2019-02-14
SI3043827T1 (en) 2019-08-30
AU2014318580A1 (en) 2016-03-03
JP2016533765A (en) 2016-11-04
EP3043827A2 (en) 2016-07-20
IL244095A0 (en) 2016-04-21
CN105744959B (en) 2020-12-01
AU2014318580B2 (en) 2019-12-12
WO2015038939A2 (en) 2015-03-19
JP2020036600A (en) 2020-03-12
LT3043827T (en) 2019-08-12
RU2662967C2 (en) 2018-07-31
EP3043827B1 (en) 2019-07-03
PE20190354A1 (en) 2019-03-07
MX2016003263A (en) 2016-12-08
CN112359042A (en) 2021-02-12
RS59252B1 (en) 2019-10-31
US11926830B2 (en) 2024-03-12
DOP2016000063A (en) 2016-06-01
EP3603677A1 (en) 2020-02-05
MX2020001258A (en) 2020-03-20
US20160222389A1 (en) 2016-08-04
SG11201601445XA (en) 2016-03-30
RU2016113763A (en) 2017-10-16
HUE045109T2 (en) 2019-12-30
MX371518B (en) 2020-01-31
KR20160054595A (en) 2016-05-16
CA2921842A1 (en) 2015-03-19
KR102381790B1 (en) 2022-03-31
MY181251A (en) 2020-12-21
CN105744959A (en) 2016-07-06
PL3043827T3 (en) 2020-03-31
CR20160170A (en) 2016-07-15
AU2020201763A1 (en) 2020-04-02
PT3043827T (en) 2019-09-26
JP7297112B2 (en) 2023-06-23
ZA201601236B (en) 2017-05-31
CL2016000606A1 (en) 2017-02-17
BR112016004671B1 (en) 2020-12-29
JP2022058784A (en) 2022-04-12
ES2745758T3 (en) 2020-03-03
PH12016500443A1 (en) 2016-05-16
HRP20191600T1 (en) 2019-11-29
EA201690582A1 (en) 2016-07-29
JP7158363B2 (en) 2022-10-21
EA035433B1 (en) 2020-06-15
PE20160500A1 (en) 2016-05-21

Similar Documents

Publication Publication Date Title
SG10201806787VA (en) Modulators of complement factor b
PH12020551397A1 (en) Cot modulators and methods of use thereof
PH12016502062A1 (en) Compositions and methods for modulating completent factor b expression
MX2018003472A (en) Modulators of kras expression.
CL2016000354A1 (en) Modulation of tumor immunity
JO3343B1 (en) Novel5-aminotetrahydroquinoline-2-carboxylic acids and their use
MX2015008685A (en) Treatment of psoriatic arthritis using apremilast.
NI201500150A (en) CANCER TREATMENT WITH DIHYDROPIRAZINE-PIRAZINES × Provided in this method
TR201902517T4 (en) Treatment of conditions associated with increased eotaxin with 25-hydroxyvitamin D3.
GT201200345A (en) HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPY APPLICATION
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
CL2016001428A1 (en) Use of a composition with cognitive exercises useful for the prevention or treatment of delayed cognitive development in children.
PH12017500084A1 (en) Vitamin b2 and its use
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
UA87629U (en) Method for preventing and correcting difficulties in adapting foreign students to new conditions of life and study load
UA84302U (en) Method for correcting immune state in patients with recurrent depressive disorder
CR20190329A (en) MODULATORS OF COMPLEMENT FACTOR Bi
UA74770U (en) method for treating patients with chronic hepatobiliary pathology on the background of enhanced fatigue syndrome
UY34233A (en) ANTITUMORAL COMBINATION THAT INCLUDES OMBRABULINA AND CETUXIMAB, ASSOCIATED WITH RADIOTHERAPY
UA84204U (en) Method for immunocorrection of patients with chickenpox and immunodeficient state
UA84195U (en) Method for treating influenza in adult patients
UA89118U (en) Method for treating antiphospholipid syndrome
UA89119U (en) Method for treating antiphospholipid syndrome